Insight into Structure-Activity Relationship of New Compounds for Breast Cancer Treatment

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Oncology

Background:

• Breast cancer remains a significant threat to women's health.
• Current treatments like chemotherapy and kinase inhibitors have limitations.
• There is a critical need for novel therapeutic agents, particularly for triple-negative breast cancer (TNBC).

Purpose of the Study:

• To review novel compounds with anti-breast cancer activity.
• To analyze compound design strategies and structure-activity relationships (SAR).
• To identify promising avenues for future breast cancer drug development.

Main Methods:

• Compilation of over 100 novel anti-breast cancer compounds from public databases.
• Review of compound design strategies, including conformational constraint and scaffold-hopping.
• Analysis of structure-activity relationship (SAR) studies focusing on optimizing efficacy and pharmacokinetic properties.

Main Results:

• Novel compounds exhibit diverse mechanisms of action, including kinase inhibition, epigenetic modulation, dual inhibition, targeted protein degradation, and metal complexation.
• Key design strategies involve merging pharmacophores and scaffold-hopping.
• SAR studies aim to enhance activity, selectivity, membrane permeability, and reduce toxicity.

Conclusions:

• Structural optimization of kinase inhibitors, microtubule-targeted agents, and metal complexes may yield superior breast cancer treatments.
• Epigenetic inhibitors, dual inhibitors, and degraders represent emerging strategies for breast cancer therapy.
• Further research into these novel compounds holds promise for advancing breast cancer treatment paradigms.